FSD Pharma Inc. (CNSX:HUGE) debuts on the Canadian Securities Exchange alongside Medmen today. The company operates as FV Pharma Inc. , and has received all of the necessary exchange and regulatory approvals and will trade under the symbol “HUGE”. The company will be seeking a similar investor response.
FV Pharma’s main calling card at the moment in an large 620,000 square foot facility and exceptional land package totaling 70 acres. The licensed producer is currently growing medical cannabis in an initial 20,000 square foot limited footprint. The company intends on expanding the footprint 10-fold later this year, with the mission to transform the facility into the largest hydroponic indoor cannabis facility in the world.
The company has notable and deep entanglements with Cannabis Wheaton Income Corp. As a streaming partner, CBW will receive a 49.9% stream of all cannabis (or cannabis-derived products including any immature cannabis plants and any cannabis trim) produced at the Facility, under partnership with Cannabis Wheaton, in perpetuity. CBW’s CEO, Chuck Rifici, sits on the Board of Directors. In return, FV Pharma gets ongoing financial, design, expertise and operational support.
The company’s remarkable capital structure consists of:
(a) 15,000 Class A Multiple Voting Shares;
(b) 1,319,600,458 Class B Subordinate Voting Shares;
(c) 100,000,000 Corporation Options
(d) 112,242,457 Corporation Warrants
It should be a noteworthy day on the CSE tomorrow, as it’s rare to have two new cannabis issues IPO on a single day. Midas Letter will update the progress of both FV Pharma and Medmen as further events warrant.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.